Vaxart

Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Vaxart Inc

News

Management

Press Releases

Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D. from the Board of Directors

Vaxart to Present at the H.C. Wainwright Global Investment Conference on September 8, 2025

Vaxart Announces Adjournment of Special Meeting of Stockholders

Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting

Health Care

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

Vaxart Appoints W. Mark Watson as Lead Independent Director

Concerned Vaxart Stockholders Respond to Inadequate Governance Announcements

Vaxart Announces Withdrawal of Reverse Stock Split Proposal

Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025

Vaxart to Present Research on Second-Generation Norovirus Oral Pill Vaccine Candidate at IDWeek 2025

VXRT

B. Riley Securities

Oppenheimer

Cantor Fitzgerald

Comments

Vaxart

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL